Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2024-09-23 DOI:10.1002/14651858.CD015896

Tibor A Zwimpfer, Hannah Ewald, Esra Bilir, Madawa Jayawardana, Christian Appenzeller-Herzog, Nicolò Bizzarri, Zoia Razumova, Joanna Kacperczyk-Bartnik, Viola Heinzelmann-Schwarz, Michael Friedlander, David Dl Bowtell, Dale W Garsed

引用次数: 0

Abstract

Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.

查看原文本刊更多论文

同源重组缺陷状态对原发性输卵管卵巢高级别浆液性癌生存结果的预测价值。

目标：这是一份 Cochrane 综述（预后）协议。目标如下与 BRCA1/2 基因突变状态相比，评估分期开腹手术时通过各种临床验证的 HRD 检测方法确定的预后因素 HRD 状态对输卵管卵巢高级别浆液性癌患者无进展生存期和总生存期的预测价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.